Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gryllus bimaculatus ethanol extract (GBE) is a natural product derived from the two-spotted cricket, an edible insect used in traditional medicine. It is prepared by extracting dried and ground crickets with 70% ethanol. GBE is rich in proteins and unsaturated fatty acids and has demonstrated a range of pharmacological activities in preclinical models, including anti-thrombotic, anti-inflammatory, antioxidant, and hepatoprotective effects. Its mechanism of action involves the inhibition of platelet glycoprotein IIb/IIIa (integrin αIIb/β3) for anti-platelet activity, modulation of the AKT/mTOR pathway for metabolic effects, and induction of apoptosis in cancer cells. It is primarily studied in academic research for potential applications in cardiovascular disease, liver disease, and metabolic disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gryllus bimaculatus ethanol extract.